PBH Prestige Consumer Healthcare Inc. Insider Trading

PBH CEO Ronald M. Lombardi sold 10,875 shares for $898,240.83 on Nov 19; stock at 52-week high.

CEO Ronald M. Lombardi executed 2 separate sales totaling 10,875 shares for $898,240.83 on 2024-11-19 at an average price of $82.60, reducing his holdings by 3.3% to 321.0K shares. The sales occurred as PBH trades at $84.14, its 52-week high, following a +17.3% surge over the past 30 and 90 days. Lombardi's cross-ticker track record shows a 100.00% well-timed rate on 6 prior sells with a -10.2% average 90-day return, while his same-ticker history at PBH (3 measurable prior sales in 2023) was similarly well-timed, with negative 90-day returns of -8.1%, -9.6%, and -10.9%. The filing warrants tracking of forward returns to evaluate whether this sale at the 52-week high aligns with Lombardi's demonstrated pattern of selling before subsequent declines.

CEO Ronald M. Lombardi sells 82,237 shares of PBH for $6.8M at blended average $82.56, reducing holdings by 20.4%

Ronald M. Lombardi, Chief Executive Officer of Prestige Consumer Healthcare Inc., executed 2 separate sales totaling 82,237 shares for $6,789,764.29 on 2024-11-18, with transaction prices of $82.67 and $82.41 respectively. His post-transaction holdings of 320,952 shares represent a 20.4% reduction from pre-transaction holdings of 403,189 shares. The stock is currently trading at $82.46, only 0.4% below its 52-week high of $82.79, following a +13.7% gain over the past 30 days and +17.6% over 90 days. His prior sells at PBH (3 trades in August 2023) were all well-timed, with negative 90-day returns ranging from -8.1% to -10.9%, establishing a 100% timing pattern at this ticker.

CFO Sacco sells 24,686 shares of PBH at $82.01 for $2.0M, reducing holdings by 45.0% while stock sits at 52-week high.

Sacco Christine, CFO of Prestige Consumer Healthcare, executed a substantial open-market sale of 24,686 shares at $82.01 on 2024-11-12, reducing her holdings from 54,809 to 30,123 shares (a 45.0% reduction). The transaction occurred at the 52-week high of $82.79, with the current price at +0.0% from that peak. Across her prior five trades at PBH, Sacco's timing has been mixed: three of five were well-timed at the 90-day mark (meaning the stock declined after), though her two most recent PBH sells in February 2024 saw the stock rise 9.7% and 9.2% in the 30 days following. Her cross-ticker track record shows a 60.00% well-timed rate on sells (average 90-day return +1.0%), indicating moderate predictive accuracy historically. The current sale at the 52-week high, combined with a substantial reduction of nearly half her position, aligns with historical moments when she has exited, though the outcome—whether this proves well-timed—remains to be observed in the coming quarters.